Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2007-02-20
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S217080, C514S237200, C514S326000, C514S343000, C514S406000, C514S422000, C540S602000, C544S141000, C546S208000, C546S278400, C548S364100, C548S527000, C548S530000
Reexamination Certificate
active
10495586
ABSTRACT:
The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.
REFERENCES:
patent: 5703208 (1997-12-01), Semple et al.
patent: 5719296 (1998-02-01), Acton et al.
patent: 5932733 (1999-08-01), Semple et al.
patent: 6034215 (2000-03-01), Semple et al.
patent: 6187797 (2001-02-01), Pruitt et al.
patent: 6281227 (2001-08-01), Choi-Sledeski et al.
patent: 41 21 947 (1993-01-01), None
patent: 365992 (1990-05-01), None
patent: 1 031 563 (2000-08-01), None
patent: WO 93/01208 (1993-01-01), None
patent: WO-9535311 (1995-11-01), None
patent: 95/35313 (1995-12-01), None
patent: WO-9716425 (1997-05-01), None
patent: 98/16523 (1998-04-01), None
patent: 98/25611 (1998-06-01), None
patent: WO-9918074 (1999-04-01), None
patent: 99/62904 (1999-12-01), None
patent: 00/47563 (2000-08-01), None
patent: WO-0107407 (2001-02-01), None
patent: 01/19795 (2001-03-01), None
patent: 01/39759 (2001-06-01), None
patent: 01/79261 (2001-10-01), None
Acton et al., STN International (2005) HCAPLUS Database, Accession No. 1998:146592, Reg. No. 190377-96-9.
Acton et al., STN International (2005) HCAPLUS Database, Columbus, OH, Accession No. 1998:146592, Reg. No. 190377-96-9.
Semple, J.E., “Design, sytnehsis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-4 lactam sulfonamide moieties,”Journal of Medicinal Chemistry, vol. 39, No. 23, 1996, pp. 4531-4536.
Semple, J.E. et al., “Rational design and synthesis of a novel, selective class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4, quaternary lactam dipeptide surrogates,”Bioorganic&Medicinal Chemistry Letters, vol. 7, No. 18,997, pp. 2421-2426.
J. Med. Chem.; 1996; 4531-4536; 39(23).
Pept. 1996, Proc. Eur. Pept. Symp., 24th; 1996; 71-74.
Young et al., “Structure-and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs,”Bioorganic & Medicinal Chemistry Letters, 2006, doi:10.1016/j.bmcl.2006.09.0001.
Borthwick Alan David
Campbell Matthew
Chan Chuen
Kelly Henry Anderson
King Nigel Paul
Fix Amy H.
Freistein Andrew B.
Glaxo Group Limited
Saeed Kamal A.
LandOfFree
2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810500